LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.05 -3.67

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.05

Max

1.08

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Aktsiakasum	-0.27
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+362.96% upside

Turustatistika
By TradingEconomics
Turukapital	-6.9M 119M
Eelmine avamishind	4.72
Eelmine sulgemishind	1.05

Uudiste sentiment

By Acuity

25%

75%

59 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. dets 2025, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Brookfield, GIC Agree $4.5 Billion Deal for Australia's National Storage -- Update

5. dets 2025, 21:08 UTC

Omandamised, ülevõtmised, äriostud

Meta Platforms Buys AI-Device Maker Limitless

5. dets 2025, 19:39 UTC

Suurimad hinnamuutused turgudel

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5. dets 2025, 19:17 UTC

Omandamised, ülevõtmised, äriostud

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

7. dets 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

7. dets 2025, 23:05 UTC

Market Talk

RBA Set to Remain 'Emphatically' On Hold, Westpac Says -- Market Talk

7. dets 2025, 22:18 UTC

Market Talk

RBA Set To Conclude Year With Hawkish Message -- Market Talk

6. dets 2025, 16:52 UTC

Omandamised, ülevõtmised, äriostud

As Netflix Swoops In to Buy Warner Bros., We Revisit the Studio's Long, Twisted Journey -- Barrons.com

6. dets 2025, 10:30 UTC

Omandamised, ülevõtmised, äriostud

Why Netflix Shareholders Aren't Thrilled to Acquire Warner Bros. -- Heard on the Street -- WSJ

6. dets 2025, 02:38 UTC

Omandamised, ülevõtmised, äriostud

How a Netflix-Warner Deal Would Change Everything in Hollywood -- Again -- WSJ

5. dets 2025, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5. dets 2025, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

5. dets 2025, 21:50 UTC

Omandamised, ülevõtmised, äriostud

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5. dets 2025, 21:36 UTC

Market Talk

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5. dets 2025, 21:35 UTC

Omandamised, ülevõtmised, äriostud

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5. dets 2025, 21:26 UTC

Omandamised, ülevõtmised, äriostud

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5. dets 2025, 21:12 UTC

Market Talk

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5. dets 2025, 21:03 UTC

Market Talk

Tulu

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5. dets 2025, 21:01 UTC

Market Talk

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5. dets 2025, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5. dets 2025, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5. dets 2025, 20:42 UTC

Omandamised, ülevõtmised, äriostud

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5. dets 2025, 20:01 UTC

Omandamised, ülevõtmised, äriostud

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5. dets 2025, 19:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. dets 2025, 19:44 UTC

Market Talk

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5. dets 2025, 19:39 UTC

Market Talk

Silver Climbs to a New Record High -- Market Talk

5. dets 2025, 19:31 UTC

Omandamised, ülevõtmised, äriostud

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5. dets 2025, 18:30 UTC

Market Talk

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5. dets 2025, 18:28 UTC

Omandamised, ülevõtmised, äriostud

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5. dets 2025, 18:24 UTC

Omandamised, ülevõtmised, äriostud

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

362.96% tõus

12 kuu keskmine prognoos

Keskmine 5 USD 362.96%

Kõrge 8 USD

Madal 2 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

59 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.